Tag: receptor tyrosine kinases

Shanghai (China) base CStone Pharmaceuticals has submitted a Phase 1b clinical trial application in Australia for CS5001, a receptor tyrosine kinase-like orphan receptor 1 (ROR1-) targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for the treatment of Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL).

Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with to evaluate the combination of...

Celldex Therapeutics has entered into a definitive agreement to acquire Kolltan Pharmaceuticals, a clinical-stage company focused on the discovery and development of novel, antibody-based drugs...